CUTA: A Protein with Potential as A Drug Target and Biomarker

Target Name: CUTA

NCBI ID: G51596

CUTA

CUTA: A Protein with Potential as A Drug Target and Biomarker

CUTA (CUTA variant 1) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the heat shock protein (HSP) family, which are proteins that are expressed in high abundance in response to an increase in temperature.

CUTA has been shown to play a role in the regulation of various cellular processes, including cell survival, metabolism, and stress response. It has also been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of CUTA is its potential as a drug target. CUTA has been shown to interact with a variety of molecules, including transcription factors, signaling proteins, and metabolic enzymes. This makes it an attractive target for small molecules and other therapeutic agents that can modulate its activity.

One of the first drugs to be developed specifically to target CUTA was a small molecule called U21905. U21905 is a purine nucleoside that inhibits the activity of CUTA by binding to its alpha-helices. This drug was shown to be effective in animal models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another drug that is being developed to target CUTA is a monoclonal antibody called Aducanumab. Aducanumab is a type of antibody that is designed to bind to CUTA and prevent it from interacting with its cognate protein, alpha-helices. This drug is being shown to be effective in clinical trials for the treatment of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, CUTA is also being investigated as a biomarker for various diseases. For example, CUTA has been shown to be elevated in the brains of individuals with Alzheimer's disease, and it is also expressed in the blood of individuals with Parkinson's disease. This suggests that CUTA may be a useful biomarker for the diagnosis and treatment of these diseases.

Overall, CUTA is a protein that has significant potential as a drug target and biomarker. Its ability to interact with a variety of molecules makes it an attractive target for small molecules and other therapeutic agents that can modulate its activity. Further research is needed to fully understand the role of CUTA in various biological processes and to develop effective treatments for the diseases that are associated with its expression.

Protein Name: CutA Divalent Cation Tolerance Homolog

Functions: May form part of a complex of membrane proteins attached to acetylcholinesterase (AChE)

The "CUTA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CUTA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets